<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096938</url>
  </required_header>
  <id_info>
    <org_study_id>cancer screening</org_study_id>
    <nct_id>NCT03096938</nct_id>
  </id_info>
  <brief_title>Cell-free DNA Methylation Markers for Cancer Screening</brief_title>
  <official_title>Cell-free DNA Methylation Markers for Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of cell-free DNA methylation markers in
      cancer screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity (true positive rate)</measure>
    <time_frame>2 year</time_frame>
    <description>The proportion of persons with disease who have a positive test (positive test results among persons with disease)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity (true negative rate)</measure>
    <time_frame>2 year</time_frame>
    <description>The proportion of persons without disease who have a negative test (negative test results among persons without disease)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Cancer Screening</condition>
  <arm_group>
    <arm_group_label>Normal screening group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive the routine screening examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylation markers screening group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive the methylation markers screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>methylation markers screening</intervention_name>
    <description>Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis</description>
    <arm_group_label>Normal screening group</arm_group_label>
    <arm_group_label>methylation markers screening group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is average risk for development of cancer

          2. Subject able and willing to undergo screening test within 90 days of enrollment

          3. Subject is 40 to 74 years of age inclusive

          4. Subject is able to comprehend, sign, and date the written informed consent document to
             participate in the study

        Exclusion Criteria:

          1. Subject has any condition which, in the opinion of the investigator should preclude
             participation in the study

          2. Subject has a history of cancer

          3. Participation in any &quot;interventional&quot; clinical study within the previous 30 days in
             which an experimental treatment is administered or might be administered through a
             randomized assignment of the subject to one or more study groups.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-yan Luo, MD.PhD.</last_name>
      <phone>862087343008</phone>
      <email>luohy@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Rui-hua Xu, MD.PhD.</last_name>
      <phone>862087343228</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.</citation>
    <PMID>24645800</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>December 25, 2017</last_update_submitted>
  <last_update_submitted_qc>December 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ruihua Xu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>cell-free DNA</keyword>
  <keyword>methylation</keyword>
  <keyword>markers</keyword>
  <keyword>cancer</keyword>
  <keyword>screening</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

